STAAR Surgical Company (STAA) fair value analysis

Nasdaq · Updated 2026-09-07

STAAR Surgical Company designs and manufactures implantable lenses and related surgical equipment used in ophthalmology procedures, particularly for vision correction. The company operates globally, serving customers in markets across North America, Europe, Asia, and other regions worldwide.

Forward Fair Value verdict

Undervalued

Based on TickrTrends' weekly Forward Fair Value model, STAA is trading at more than a 25% discount to estimated fair value.

STAA currently ranks #13 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 3 consecutive weekly runs.

Last price: $24.34
Sector: Healthcare
12-month range: $18.04–$29.55

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: D
Leverage: Low
RSI zone: Neutral
50/200-day trend: Mixed
52-week position: The upper-middle quarter of its range

What our data shows for STAA

Our model validated 12 trailing price-to-earnings windows for STAA, built from quarterly earnings records.
Shares are trading in the middle of their 12-month price range of $18.04–$29.55.
The 14-day relative strength index sits at a neutral 54.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for STAA
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent STAA news

TickrTrends' derived news-sentiment signal for STAA is currently leaning positive, computed from recent coverage.

STAA Looks 30.9% Undervalued on GF Value™ Despite Profitability Challenges (gurufocus.com, 2026-09-02)
TickrTrends take: STAA's Healthcare sector positioning combined with TickrTrends' undervalued designation aligns with the GF Value assessment suggesting notable price appreciation potential if the company can stabilize its profitability trajectory. Investors tracking valuation metrics should monitor whether operational challenges persist or if margin improvements emerge, as these factors will determine whether the current discount reflects genuine opportunity or appropriate caution. The gap between market price and intrinsic value estimates creates a scenario where fundamental business performance becomes the primary driver of whether this valuation advantage materializes into returns.
Staar surgical plans to end 2026 with well over $200M in cash while shifting 100% of China supply to Switzerland (NASDAQ:STAA) (seekingalpha.com, 2026-08-13)

What people are saying

Follow the STAA conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is STAA stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), STAA is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.

What is STAA's TickrTrends verdict?

STAA's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.

How does STAA compare to other Healthcare stocks?

STAA ranks #13 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is STAA overbought or oversold?

STAA's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

STAA vs ALGN · STAA vs AMPH · STAA vs ANIP · STAA vs BSX · STAA vs COO